Literature DB >> 6313012

Comparative cardiac oxygen radical metabolism by anthracycline antibiotics, mitoxantrone, bisantrene, 4'-(9-acridinylamino)-methanesulfon-m-anisidide, and neocarzinostatin.

J H Doroshow, K J Davies.   

Abstract

This study examined the effects of various anthracycline antibiotics and mitoxantrone, bisantrene, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA), and neocarzinostatin on oxygen radical formation by cardiac sarcoplasmic reticulum and submitochondrial particles. Doxorubicin, daunorubicin, rubidazone, and aclacinomycin A stimulated superoxide production by both heart fractions in a dose-dependent fashion that appeared to follow saturation kinetics. The anthracycline drugs also significantly increased hydrogen peroxide production by heart sarcosomes and submitochondrial particles. On the other hand, mitoxantrone, bisantrene, m-AMSA, and neocarzinostatin did not significantly enhance cardiac reactive oxygen metabolism. Thus, it is unlikely that the mechanism of the cardiac toxicity produced by mitoxantrone and m-AMSA in patients previously treated with anthracycline drugs can be directly related to oxidation-reduction cycling catalyzed by cardiac flavin dehydrogenases.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313012     DOI: 10.1016/0006-2952(83)90399-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes.

Authors:  Laura A A Gilliam; Jennifer S Moylan; Elaine W Patterson; Jeffrey D Smith; Anne S Wilson; Zaheen Rabbani; Michael B Reid
Journal:  Am J Physiol Cell Physiol       Date:  2011-09-21       Impact factor: 4.249

Review 2.  Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.

Authors:  Laura A A Gilliam; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2011-06-15       Impact factor: 8.401

Review 3.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

4.  Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer.

Authors:  M Bontenbal; A S Planting; C J Rodenburg; A Dees; J Verweij; C C Bartels; J Alexieva-Figusch; W L van Putten; J G Klijn
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 5.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

6.  Microsomal lipid peroxidation induced by adriamycin, epirubicin, daunorubicin and mitoxantrone: a comparative study.

Authors:  G F Vile; C C Winterbourn
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 7.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

Review 8.  Beyond oxidative stress: an immunologist's guide to reactive oxygen species.

Authors:  Carl Nathan; Amy Cunningham-Bussel
Journal:  Nat Rev Immunol       Date:  2013-05       Impact factor: 53.106

9.  The effects of doxorubicin and mitoxantrone on wound healing.

Authors:  R Noh; G I Karp; D F Devereux
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.

Authors:  B C Goh; E E Vokes; A Joshi; M J Ratain
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.